YEARS算法在癌症患者疑似肺栓塞诊断中的随机临床试验
Hydra研究为开放标签、随机、非劣效性试验,纳入698例活动性癌症疑似急性肺栓塞患者,比较YEARS算法与仅CTPA的诊断管理。YEARS组排除肺栓塞后90天内主要结局为1.8%,仅CTPA组为5.5%,绝对风险差-3.7%(99.9%CI -8.8%至1.4%),非劣效性成立;YEARS组22%患者未行CTPA。
要点
- 癌症疑似肺栓塞患者中,YEARS算法排除肺栓塞后90天血栓栓塞或肺栓塞相关死亡风险不劣于仅CTPA。
- YEARS组282例中5例(1.8%)发生主要结局,仅CTPA组273例中15例(5.5%),绝对风险差-3.7%。
- YEARS组352例中77例(22%)未行CTPA即完成诊断管理,两组CTPA阴性比例无差异(P=.93)。
主要发现
- 符合方案YEARS组排除肺栓塞的282例中5例(1.8%)发生主要结局,仅CTPA组273例中15例(5.5%)发生主要结局,绝对风险差-3.7%(99.9%CI -8.8%至1.4%;非劣效性P=3.4×10^-5)。
- 意向诊断分析中YEARS算法与仅CTPA的绝对风险差为-2.6%(99.9%CI -7.5%至2.4%;非劣效性P=5.9×10^-4)。
- YEARS组352例中77例(22%)未行CTPA即完成肺栓塞诊断管理。
- 两组CTPA阴性比例无差异(P=.93)。
关键数值与推荐
- 主要结局为基线排除肺栓塞后90天内中心裁定的症状性静脉血栓栓塞或(可能的)肺栓塞相关死亡。
- 非劣效性界值为单侧99.9%CI上限2.6%。
- YEARS算法包括评估YEARS条目、D-二聚体水平及根据风险行CTPA。
临床怎么用
- 作者结论认为,在癌症疑似肺栓塞患者中,YEARS诊断算法与仅CTPA一样安全,使22%患者免于CTPA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JAMA . 2026 Aug 25;336(8):655-663. doi: 10.1001/jama.2026.10676. ABSTRACT IMPORTANCE: Although the YEARS algorithm is a safe and efficient way to rule out acute pulmonary embolism (PE), robust evidence on its accuracy in patients with cancer is lacking, and current guidelines suggest proceeding directly to computed tomographic pulmonary angiography (CTPA). OBJECTIVE: To compare the safety and efficiency of the YEARS algorithm with CTPA only to rule out acute PE in patients with active cancer. DESIGN, SETTING, AND PARTICIPANTS: The Hydra study was an open-label, randomized, investigator-initiated, noninferiority trial with blinded central outcome adjudication conducted from August 22, 2019, to August 21, 2025, the date of final follow-up. Patients with active cancer and suspected acute PE were recruited from emergency departments or medical units in 21 hospitals in the Netherlands, Italy, Switzerland, Belgium, France, and Spain. INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive diagnostic management by the YEARS algorithm (n = 352)-consisting of assessing YEARS items, D-dimer levels, and performing risk-dependent CTPA-or by CTPA only (n = 346). MAIN OUTCOMES AND MEASURES: The primary outcome was centrally adjudicated symptomatic venous thromboembolism or (possible) PE-related death within 90 days after ruling out PE at baseline, assessed in a per-protocol noninferiority analysis with a 2.6% margin for the upper bound of a 1-sided 99.9% CI. The key secondary outcome was the proportion of negative CTPA results at baseline, assessed in a superiority analysis. RESULTS: A total of 698 patients were randomized (median age, 65 years [IQR, 56-72 years], 422 female [60%]), and 104 patients (15%) had PE diagnosed at baseline. One patient was lost to follow-up. Of those in whom PE was considered excluded, 5 of 282 patients (1.8%) in the per-protocol YEARS group vs 15 of 273 patients (5.5%) in the per-protocol CTPA-only group had a primary outcome (absolute risk difference, -3.7%; 99.9% CI, -8.8% to 1.4%; P = 3.4 × 10-5 for noninferiority). In the intention-to-diagnosis analysis, the absolute risk difference between the YEARS algorithm and CTPA only was -2.6% (99.9% CI, -7.5% to 2.4%; P = 5.9 × 10-4 for noninferiority). Diagnostic management of PE was carried out for 77 of 352 patients (22%) in the YEARS group without CTPA. No difference in the proportion of negative CTPA (P = .93) was observed between the groups. CONCLUSIONS AND RELEVANCE: In patients with cancer and suspected PE, a diagnostic strategy using the YEARS diagnostic algorithm was as safe as using CTPA only, thus, obviating the need to perform CTPA in 22% of patients. Trial registration ccmo.nl Identifier: NL-OMON52383.
引用
- PubMed 顶刊 · 肺栓塞:YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。